Company intelligence / Profile preview

Alphina Therapeutics

New Haven, Connecticut, United Statesalphinatx.com ↗

Ownership: Private
Employees: ~17
Development stage: Preclinical

Overview

Alphina Therapeutics is advancing a proprietary small molecule NAMPT inhibitor for the treatment of various solid tumors. Their approach leverages novel biomarkers and synthetic lethality to improve efficacy and reduce toxicity compared to previous attempts at targeting this pathway. They have developed a proprietary patient selection assay to identify patients most likely to benefit from their therapy.

Therapeutic areas: Oncology
Modalities: Small molecules (NAMPT inhibitors)
Industry: Biotech

Partnerships

No major pharmaceutical partnerships disclosed as of May 2025.

Beyond the preview

Go deeper on Alphina Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alphina Therapeutics.

Explore the full profile